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Systemic Lupus Erythematosus (SLE) 
 
by Jennifer Pope 
 
(Anatomy & Physiology 1551) 
 
 
 
n expansive range of symptoms appears and attacks without warning, has no known 
cause, and there is no known cure-Lupus. Systemic Lupus Erythematosus is called by 
the Lupus Foundation of America, Inc. (2016), "The Cruel Mystery". This paper will 
define Systemic Lupus Erythematosus (SLE or Lupus), explain the links thought to contribute to 
the etiology, list the common symptoms of SLE and health effects, and outline the current 
treatment options and research. The cruel mystery of lupus sterns from its health effects ranging 
from a butterfly shaped rash, stroke, heart attack, organ inflammation, to hair loss ("What", 
2016, p.l). The Lupus Foundation estimates that there are 1.5 million Americans who have a 
form of lupus and about 5 million people through the world ("Statistics", 2016, p.l). The 
symptoms and health effects of SLE are many, but the cure and cause are still a mystery. 
 SLE is an autoimmune disease where the immune system makes autoantibodies that 
attack and destroy healthy tissue, which can cause inflammation and damage. Daniel J. Wallace, 
MD in his book The Lupus Book (2013) says, "In simple terms, lupus erythematosus develops 
when the body becomes allergic to itself ...In lupus, the body overreacts to an unknown stimulus 
and makes too many antibodies, or proteins directed against the body tissue. Thus, lupus is called 
an autoimmune disease (auto meaning self)" (p. 5). The immune system is the body system that 
produces proteins called antibodies that destroy foreign threats. However, the immune system of 
a person with SLE malfunctions and creates autoantibodies that attack some of the healthy cells 
in tissues and organs. These autoantibodies continue to destroy healthy tissue and other immune 
cells join; thus, leading to inflammation (Starkebaum, Zieve, Oglivie, & A.D.A.M. Editorial 
team, 2015, p.l). A more in depth look at the pathophysiology can be obtained from The Lupus 
Book (2013) by Daniel J. Wallace M.D. where he describes the enemy is in the cells. 
 
Neutrophils (the white blood cells responsible for mediating acute inflammation) 
can increase inflammation in the body of lupus sufferers because of the way their 
blood plasma interacts with cytokins, complement, and adhesion molecules (the 
chemicals that draw cells closer to the site of inflammation). Lymphocytes, the 
white blood cells responsible for chronic inflammation, also have their function 
altered in lupus. The T- helper cells become more active, and the body becomes 
less responsive to T-suppressor cells. Natural killer lymphocytes promote 
inflammation and are not able to suppress or contain it. As a result, the body's 
system of tolerance is disrupted so much that B cells are signaled to make 
antibodies to the patient's own tissues, which are called autoantibodies. (p.27) 
 
The normal immune system is changed in a person with lupus at the cellular level as the 
inflammatory responses and production of antibodies are at a higher rate, making an 
immunological abnormality. The autoantibodies are a key indicator of lupus. Daniel J. Wallace 
M.D. lists the antibodies in lupus patients in his book mentioned above. 
 
A 
1
Pope: Systemic Lupus Erythematosus (SLE)
Published by DigitalCommons@COD, 2016
115 
These include antibodies that form against materials in the nucleus or center of the 
cell, such as antinuclear antibody, anti-DNA, anti-Sm, anti-RNP, and antihistone 
antibody; antibodies that form against cytoplasm or cell surface components, such 
as anti-Ro (SSA), anti-La (SSB), antiphospolipid, and antitribosomal blood cells, 
platelets, or nerve cells; and antibodies that form against circulating antigens, such 
as rheumatoid factors and circulating immune complexes. (p. 27) 
 
 The existence of these antibodies can be indicators to help diagnose patients, but the 
presence in blood tests is not enough diagnostic criteria to be fully conclusive. Antiphospholipid 
antibodies are made to destroy phospholipids and associated blood proteins. According to John 
Hopkins webpage "How lupus affects the body" (2016), fifty percent of lupus patients have these 
antibodies and may experience a blood clot. Antibodies can attack nerve cells and blood vessels 
impeding blood flow in the nervous system leading to cognitive issues, headaches, or vasculitis 
in the main nervous system (p.1). The inflammation in organs for lupus patients is due to the 
deposit of this immune complex (Wright & Bharadwaj, 2010, p.1). 
 Understanding the pathophysiology of lupus in the body brings forth the question of what 
the etiology is. According to the Center for Disease Control (CDC), lupus primarily occurs in 
women approximately four to twelve women for every man, and more frequently occurring in the 
childbearing years for females. The CDC states, "Blacks (and probably Hispanics, Asians, and 
Native Americans) are affected more than whites. People with a family history of SLE or other 
autoimmune diseases are at slightly higher risk for developing SLE" ("Systemic", 2015, p.1). 
Even with these concentrations of who is affected by lupus it truly can affect any gender, race, 
ethnicity, and age ("What", 2015, p.1). The CDC's webpage "systemic lupus erythematosus" 
says, "Among rheumatic conditions, SLE has a relatively high mortality (14.5% of all rheumatic 
disease mortality in 1997" (p.1). There has been improved diagnosis and management of the 
disease, but it is believed that approximately 10-15% of people with lupus will die due to 
complications ("Statistics", 2016, p.1). People with lupus can die from kidney disease, heart 
attacks, and related cardiovascular diseases. So, it is important for those with lupus to lead a 
healthy lifestyle lowering risk factors for heart disease ("What are the most", 2013, p.1). The 
research done thus far has found some trends or links to a possible cause yet inconclusive. 
 According to John Hopkins Lupus Center website (2016), the number one lupus center in 
America, there are links between lupus and genes, hormones, and environmental factors. Genes 
may have a role in lupus as the MHC class II and III are genes that make codes for proteins that 
interact with antigens and involve the inflammatory response. The malfunction of these genes is 
associated with lupus. The other genes linked to lupus are the genes that create the coding for 
opsonins, complement receptors, and antibody receptors ("Causes", 2016, p.1). 
 The second element in the etiology complexity of lupus are hormones. According to The 
John Hopkins Lupus Center (2016), women are nine times more likely to develop lupus than 
men. The higher levels of the female sex hormone estrogen enhance the function of the immune 
system. Women notice more symptoms around the menstrual cycle as well. "For this reason, the 
incidence of autoimmune diseases is generally higher in women than in men" ("Causes", 2016, 
p.1). 
 The third element in the etiology complexity of lupus is environmental. According to The 
John Hopkins Lupus Center, "These environmental contributors are difficult to isolate, but 
researchers have established links between lupus and a variety of toxins, such as cigarette smoke, 
silica, and mercury. Infectious disease agents such as the Epstein-Barr Virus (EBV, which causes 
mononucleosis or "mono"), herpes zoster virus (the virus that causes shingles), and 
cytomegalovirus have also been implicated" ("Causes", 2016, p.1). There has been links between 
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certain drugs springing the onset of lupus symptoms, and ultraviolet light has been shown to 
agitate lupus. 
 Though the cause of lupus is still a mystery, the symptoms and related conditions are vast 
and at times cruel. Symptoms vary in every patient and can come and go through periods where 
there is a flare up of symptoms and periods where there is dormancy. According to the CDC, 
"Patients with SLE have an increased frequency of other autoimmune problems, such as Sjogren's 
syndrome (i.e., dry eyes, dry mouth) and antiphospholipid syndrome (i.e., cloting problems, 
strokes, fetal loss) that require additional treatments" ("Systemic", 2015, p.l). Other common 
symptoms are fatigue, fever, malaise, mouth sores, hair loss, butterfly shape rash, ultraviolet light 
sensitivity, swollen joints, and dizziness. The nervous system can be affected and result in 
headaches, numbness, tingling, seizures, vision problems, and personality change. The digestive 
system can be affected causing abdominal pain and nausea. The cardiovascular system can be 
affected causing arrhythmias. The respiratory system can be affected causing difficulty 
breathing in the lungs (pleurisy). The integumentary system may be affected causing patchy skin 
color or sores known as discoid lupus. The vascular system and circulatory system can be 
affected if Raynaud phenomenon develops causing a narrowing of blood vessels. The kidneys are 
a common organ that can become inflamed as lupus attacks (Starkebaum, Zieve, Oglivie, & 
A.D.A.M. Editorial team, 2015, p.l). The American College of Rheumatology article 
"Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults" indicates 
the uncertainty of symptoms and severity that can ensue. "In addition to the persistent risk of 
disease flares, more than one-half of SLE patients may develop permanent organ system 
damage" (Hahn, B.H. et al., 2012, p.l). As the body is working against itself this can give rise to 
uncertainty and fear in patients. 
 The pain and fatigue can interfere with everyday life, and quality of life has been 
researched as well. In a qualitative study on uncertainties and opportunities in lupus patients by 
Mattsson, M., Moller, B., Stamm, T., Gard, G., and Bostrom, C., one participant said," '...It's 
so inconsistent, so to speak, it's so variable. I often say SLE is cancer number two, because you 
don't know if you will be able to be so very lively today, but you'll be having a flare-up next 
week, just like that, it's so very unpredictable ...'(lB)" (Mattsson, Moller., Stamm, Gard., & 
Bostrom 2015). There is a need for more research on the occupational therapy and counseling 
aspects to help patients cope with the physical, cognitive, and emotional impacts. From Jill 
Buyon's Abstract for "Systemic lupus erythematosus" (2015), she describes the complexity of the 
disease in relation to symptoms and manifestation as follows. 
 
Indeed, it is the diversity of presentation, accumulation of manifestations over 
time, and undulating disease course that challenge the most astute of clinicians. 
With rare exception, the unifying laboratory abnormality is the presence of 
circulating antinuclear antibodies (ANA). Acknowledging the complexity of this 
disease, its broad differential diagnosis, and the need to develop better and more 
specific therapies, the American College of Rheumatology (ACR) has designated 
11 diagnostic criteria ...The presence of four or more criteria is required for 
diagnosis. They need not necessarily present simultaneously: a single criterion 
such as arthritis or thrombocytopenia may recur over months or years before the 
diagnosis can be confirmed by the appearance of additional features. (Buyon, J., 
2015, p.1) 
 
 With this being said, symptoms and severity vary from patient to patient and it is 
unpredictable the exact course the disease may take. The Systemic Lupus International 
Collaborating Clinics (SLICC) group revised and validated the ACR criteria for lupus. The 
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following summarizes the final criterion established from Table 3 in the article "Derivation and 
validation of the Systemic Lupus International Collaborating Clinics classification criteria for 
systemic lupus erythematosus"(2012). Clinical criteria include the following major classifications 
which include acute cutaneous lupus, chronic cutaneous lupus, oral ulcers, nonscarring alopecia, 
synovitis involving two of more joints over thirty minutes, serositis, renal showing urine protein-
to-creatinine ratio of 500mg protein or red blood cell casts, neurologic (seizures, psychosis, 
mononeuritis multiplex, peripheral or cranial neuropathy, acute confusional state), hemolytic 
anemia, leukopenia, thrombocytopenia. The immunological criteria list is ANA level above range, 
presence of Anti-dsDNA, presence of Anti-Sm, Antiphospholipid antibody positive, low 
complement (C3, C4, CH50), and Direct Coombs' test (Petri, M. et al., 2014, p.1). 
 The patient must present with four of the above criteria to be diagnosed with this disease. 
The common tests done are complete blood count, erythrocyte sedimentation rate, kidney and 
liver assessment, urinalysis, antinuclear antibody, chest X-ray, echocardiogram, and biopsy of 
kidney at times (MayoClinic Staff 2014). Once diagnosed, there are certain treatment depending 
on the symptoms. 
 There are treatment options for lupus patients depending on severity and activity such 
that the rheumatologist may have different treatments over the patient's lifetime that need to be 
followed. NSAIDS are anti-inflammatory medications that help with muscle, joint, and other 
tissue inflammation ("Lupus medications", 2016, p.1). Anti-Malarial drugs such as Plaquenil are 
used to control lupus over the lifetime helping suppress symptoms like fatigue, rashes, joint pain, 
mouth sores, and abnormal blood clotting. In certain cases, cylophosphamid (a chemotherapy 
drug) may be used to help tame the lupus activity. Steroids are synthetic cortisone medication that 
are effective at reducing the swelling, pain, and inflammation of lupus, but have many risks with 
the benefits. (Ginzler, E., Tayar, J., & American College of Rheumatology Committee, 2015, 
p.1). Immunosuppressive medications help to suppress the immune system from overworking. 
DHEA is a mild male hormone that helps with some symptoms such as hair loss, joint pain, 
fatigue, and cognitive dysfunctions (John Hopkins). When lupus starts inflaming and attacking 
the kidneys (nephritis) it can result in end-stage renal disease and there has not been a decline in 
numbers since 2004 even despite therapeutic treatments developed (Hahn, B. H. Overall, 2012, 
p.1). A newer treatment called Benlysta or belimumab approved in 2011 by the FDA for adult 
SLE sufferers, has been used to treat arthritis symptoms (Ginzler, E., Tayar, J., & American 
College of Rheumatology Committee, 2015, p.1). The reevaluation of the treatment plan, tests, 
and symptom monitoring must be through the patient's lifespan to ensure control of this disease. 
 In conclusion, SLE is an autoimmune disease that causes autoantibodies to generate and 
attack healthy tissues and creates inflammation by expanding blood vessels or complex deposits 
overtime. SLE can affect any organ and changes overtime with frequency of flares. SLE's exact 
cause is still unknown, but there are some links between a complex interplay of genes, hormones, 
and environmental factors currently being reviewed. There is a slew of symptoms involving 
multiple body systems, and they vary patient to patient. The diagnostic criteria require a person to 
have four of the criteria to be diagnosed. The Lupus Foundation of America is one of the largest 
organizations that is bringing more awareness for this disease and research. The Lupus 
Foundation of America has started a 2016 peer-reviewed research fund to study stem cells, 
environmental triggers of lupus in children and teens, and provide funding for research that has 
been delayed ("Lupus Foundation", 2016, p.1). Though lupus is deemed "The Cruel Mystery", 
there is research past and current that is helping to piece together the aspects of this mystery to 
unmask the cause and develop a cure. 
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